BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
77.56 ^USD	+0.77%		-4.28%	-19.56%

May. 17	Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104	MT
May. 15	Transcript : BioMarin Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024

April 24, 2024 at 04:03 pm EDT

BioMarin Pharmaceutical Inc. reaffirmed earnings guidance for the year 2024. For the year, the company expects there is no change in total revenues.

Latest news about BioMarin Pharmaceutical Inc.

Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104	May. 17	MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	May. 15
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing	May. 13	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	May. 06	MT
Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04	CI
BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04	CI
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	Apr. 29	MT
Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	Apr. 25	MT
Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating	Apr. 25	MT
Transcript : BioMarin Pharmaceutical Inc., Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	Apr. 24	MT
(BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95	Apr. 24	MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M	Apr. 24	MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71	Apr. 24	MT
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	Apr. 24	CI
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says	Apr. 22	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	Apr. 15	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	Apr. 01	MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM	Mar. 12
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia	Mar. 12	MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:40 AM	Mar. 11
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing	Mar. 07	MT
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer	Mar. 07	MT

Chart BioMarin Pharmaceutical Inc.

Duration

Period

More charts

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

77.56 USD

Average target price

109.3 USD

Spread / Average Target

+40.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B
INNOVENT BIOLOGICS, INC.	-6.32%	8.35B
INTRA-CELLULAR THERAPIES, INC.	-9.24%	6.86B

Biopharmaceuticals